Physicians test new narcolepsy treatments by checking whether the drugs help people to fall asleep and stay asleep throughout the night.Credit: Lucia Graphus/Alamy Earlier this month, the US Food and Drug Administration approved the first drug designed to treat the root cause of narcolepsy, a condition that affects millions of people by causing extreme sleepiness
Half a century ago, biochemists Georges Köhler and César Milstein kicked off a revolution in medicine. Their 1975 paper described how to mass-produce monoclonal antibodies: proteins that can be designed to recognize and bind specifically to almost any protein target1. These antibodies have since become a workhorse of biological research and the basis of blockbuster
Mealtime has always been a family affair for the Kochanczyks of Indiana. Dave Kochanczyk loved barbecuing, cooking Polish food, and preparing fresh vegetables from the garden. When he wasn’t in the kitchen, he led an active life, working as an electrical contractor, serving as a volunteer firefighter, and managing the family’s large rural property. Cancer
Miles Wang, an OpenAI researcher whose work includes using AI to accelerate scientific and biological discovery, is leaving the maker of ChatGPT to launch a new startup focused on developing AI models for drug discovery, according to four people with knowledge of his plans. Several other OpenAI researchers are expected to join the new company.
In 1996, cryobiologist Gregory Fahy walked into his doctor’s office and got a monthly supply of growth hormone. Your hope, reinforced by a single study in rats1was that the injections would help him grow his thymus, a peculiar immune organ that atrophies and virtually disappears as people age. Regenerating it, Fahy thought, would help it